Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases : A multicenter, questionnaire-based, cross-sectional study
© 2024 Japan Society of Hepatology..
AIM: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire-based, cross-sectional study to determine the safety and effectiveness of the SARS-CoV-2 vaccines in Japanese patients with intractable hepatobiliary disease.
METHODS: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post-vaccination adverse effects, and SARS-CoV-2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre- and post-vaccination were collected.
RESULTS: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH- primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd-Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post-vaccination adverse effects were comparable to those observed in the general population. Post-vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH-like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS-CoV-2, and only one patient was infected 6 months after the second vaccination.
CONCLUSION: SARS-CoV-2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Hepatology research : the official journal of the Japan Society of Hepatology - (2024) vom: 01. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tanifuji, Ayaka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse effect |
|---|
| Anmerkungen: |
Date Revised 01.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/hepr.14018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36789971X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36789971X | ||
| 003 | DE-627 | ||
| 005 | 20240201232412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240201s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hepr.14018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM36789971X | ||
| 035 | |a (NLM)38300669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tanifuji, Ayaka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases |b A multicenter, questionnaire-based, cross-sectional study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Japan Society of Hepatology. | ||
| 520 | |a AIM: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire-based, cross-sectional study to determine the safety and effectiveness of the SARS-CoV-2 vaccines in Japanese patients with intractable hepatobiliary disease | ||
| 520 | |a METHODS: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post-vaccination adverse effects, and SARS-CoV-2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre- and post-vaccination were collected | ||
| 520 | |a RESULTS: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH- primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd-Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post-vaccination adverse effects were comparable to those observed in the general population. Post-vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH-like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS-CoV-2, and only one patient was infected 6 months after the second vaccination | ||
| 520 | |a CONCLUSION: SARS-CoV-2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse effect | |
| 650 | 4 | |a autoimmune liver disease | |
| 650 | 4 | |a liver enzyme | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Ohfuji, Satoko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Komori, Atsumasa |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawata, Kazuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Joshita, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Umemura, Takeji |e verfasserin |4 aut | |
| 700 | 1 | |a Ueno, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Nobuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kakisaka, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Arinaga-Hino, Teruko |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kanai, Sachiko |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Arizumi, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Asaoka, Yoshinari |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohta, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuno, Suguru |e verfasserin |4 aut | |
| 700 | 1 | |a Isayama, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Youichi |e verfasserin |4 aut | |
| 700 | 1 | |a Mochida, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohira, Hiromasa |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Atsushi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology research : the official journal of the Japan Society of Hepatology |d 1998 |g (2024) vom: 01. Feb. |w (DE-627)NLM096511133 |x 1386-6346 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hepr.14018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 02 | ||